1017 - translational lessons in optimizing clinical use of bh3 mimetics to treat hematological malignancies

Oncogenic mutations impose stresses on cells which normally would trigger apoptosis. Consequently, many haematological malignancies harbour aberrations that circumvent this, most prominently dysfunction of the TP53 pathway and dysregulation of the BCL2 protein family. The prosurvival proteins BCL2 and MCL1 are commonly highly expressed in diseases like CLL, lymphomas, AML and myeloma. BH3-mimetics are a novel class of anti-cancer drugs which mimic the natural antagonists of the prosurvival proteins and operate downstream of TP53.
Source: Experimental Hematology - Category: Hematology Authors: Source Type: research